The way many bloggers are interpreting the quarterly and yearly biotech companies’ financial results seems unfair and has proven to be.
Amgen (AMGN): The stock gained over $10 yesterday and is trading now at $231. Many bloggers continue to attack the firm, mourning the loss of their protective patents on its over 30 years’ old products and ignore the record . . .